Who owns ANAVEX LIFE SCIENCES CORP. (AVXL)? Elite investor 13F holders
2 tracked elite investors reported holding ANAVEX LIFE SCIENCES CORP as of 2026-06-30, including D.E. Shaw, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine),…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | ANAVEX LIFE SCIENCES CORP | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| D.E. Shaw | ANAVEX LIFE SCIENCES CORP | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 299047.00 USD | 115462.000000 | Shares | add | Original filing |
| Tudor Investment | ANAVEX LIFE SCIENCES CORP | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 52776.00 USD | 20377.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.